—COO
— • —
$71.21
P/E
35.25
PEG
—
FCF Yield
—
Rev Growth YoY
+569.0% YoY
Gross Margin
6544.0%
Health Score
5/10
D/E Ratio
0.30
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this payload, which limits full company identification. Based on available data, this appears to be a company trading at $71.21 per share with a P/E of 35.25x and a Price/Sales of 3.35x, suggesting a mid-sized business with moderate revenue scale. Without a confirmed market capitalisation figure, the cap tier cannot be reliably classified, though the valuation ratios are consistent with a small-to-mid cap profile.
Financial Health
Score: 5/10
The balance sheet shows a conservative debt position with a Debt/Equity ratio of 0.3x, well within manageable territory. The gross margin of 6,544% and net margin of 967% are extraordinarily elevated figures that likely reflect an unusual accounting period or a very small revenue base, making them difficult to interpret with confidence at face value...
Risk Assessment
- EARNINGS DETERIORATION: Earnings growth of -236.0% YoY signals a sharp reversal in profitability despite strong headline revenue growth — a direct contradiction that warrants scrutiny.
- VALUATION PREMIUM: P/E of 35.25x is approximately 41% above the sector average of 25x, with no PEG or DCF anchor to justify the premium.
- CASH FLOW OPACITY: Free Cash Flow is unavailable, making it impossible to verify whether earnings quality is genuine or distorted by non-cash items.
- TECHNICAL DETERIORATION: A confirmed death cross (50-day MA crossing below 200-day MA) with a bearish MACD signal indicates negative price momentum across multiple timeframes.
- DATA COMPLETENESS: Missing TTM Revenue, TTM Net Income, market cap, 52-week range, and RSI limit the depth of analysis and increase uncertainty for any investment decision.
---...
**Score: 5/10** The balance sheet shows a conservative debt position with a Debt/Equity ratio of 0.3x, well within manageable territory. The gross margin of 6,544% and net margin of 967% are extraordinarily elevated figures that likely reflect an unusual accounting period or a very small revenue base, making them difficult to interpret with confidence at face value. Critically, Free Cash Flow data is unavailable, which prevents any assessment of whether reported profits translate into real cash generation — a meaningful gap in the analysis. ---
- **EARNINGS DETERIORATION:** Earnings growth of -236.0% YoY signals a sharp reversal in profitability despite strong headline revenue growth — a direct contradiction that warrants scrutiny. - **VALUATION PREMIUM:** P/E of 35.25x is approximately 41% above the sector average of 25x, with no PEG or DCF anchor to justify the premium. - **CASH FLOW OPACITY:** Free Cash Flow is unavailable, making it impossible to verify whether earnings quality is genuine or distorted by non-cash items. - **TECHNICAL DETERIORATION:** A confirmed death cross (50-day MA crossing below 200-day MA) with a bearish MACD signal indicates negative price momentum across multiple timeframes. - **DATA COMPLETENESS:** Missing TTM Revenue, TTM Net Income, market cap, 52-week range, and RSI limit the depth of analysis and increase uncertainty for any investment decision. ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives